Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cerebroside sulfatase - Takeda

Next Previous
Drug Profile

Cerebroside sulfatase - Takeda

Alternative Names: Arylsulfatase A; HGT-1110; HGT-1111; Metazym; Recombinant human arylsulfatase A; Recombinant human cerebroside sulfatase; Recombinant human sulfatidate sulfatase; rhASA; SHP-611; Sulfatide sulfatase; TAK 611

Latest Information Update: 24 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zymenex A/S
  • Developer Assistance Publique Hopitaux de Paris; Takeda; Zymenex A/S
  • Class Arylsulfatases; Recombinant proteins
  • Mechanism of Action Cerebroside sulfatase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Metachromatic leukodystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Metachromatic leukodystrophy

Most Recent Events

  • 06 May 2026 Cerebroside sulfatase completes phase II trials for Metachromatic leukodystrophy in USA, United Kingdom, Japan, Italy, Greece, Argentina, Netherlands, Belgium, Brazil, Canada, France, Germany, Israel, Mexico, Spain (EudraCT2018-003291-12) (NCT03771898)
  • 21 Apr 2026 Takeda completes a phase I/II trial in Metachromatic leukodystrophy (In neonates, In infants, In children, In adolescents, Treatment-experienced) in Japan, Germany, France, Denmark, Czech Republic, Brazil, Australia, Italy and United Kingdom (Intrathecal) (NCT01887938) (EUCT-2012-003775-20) (CTIS-2024-514403-34-00)
  • 25 Apr 2022 Cerebroside sulfatase is still in phase II trial for metachromatic leukodystrophy in USA, the UK, Japan, Italy, Greece, Argentina, the Netherlands, Belgium, Brazil, Canada, France, Germany, Israel, Mexico and Spain (EudraCT2018-003291-12; NCT03771898)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top